ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - taliglucerase alfa - אבקה להכנת תמיסה לאינפוזיה - taliglucerase alfa 200 u/vial - taliglucerase alfa - taliglucerase alfa - elelyso (taliglucerase alfa ) for injection is a hydrolytic lysosomal glucocerebroside - specific enzyme indicated for long - term enzyme replacement therapy (ert) for adults with a confirmed diagnosis of type 1 gaucher disease.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - glucose monohydrate - תמיסה לאינפוזיה - glucose monohydrate 5.5 %w/v - glucose - glucose - glucose 5 % intravenous infusion is indicated for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - glucose monohydrate - תמיסה לאינפוזיה - glucose monohydrate 5.5 %w/v - glucose - glucose - glucose 5 % intravenous infusion is indicated for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

ישראל - עברית - Ministry of Health

takeda israel ltd - velaglucerase alfa - lyophilized powder for infusion - velaglucerase alfa 400 u/vial - velaglucerase alfa - velaglucerase alfa - vpriv is a hydrolytic glucocerebroside – specific enzyme indicated for the long term replacement therapy (ert) for pediatric and adult patients with type 1 gaucher disease.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - glucose as monohydrate - תמיסה להזרקה - glucose as monohydrate 10 % - glucose - glucose - as intravenous injection: dextrose 10 % injection is indicated as a source of water and calories. as parenteral nutrient: dextrose 10 % injection is indicated as a caloric component in parenteral nutrition regimen. it is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) the alimentary tract cannot should not be used. 2) gastrointestinal absorption of protein is impaired, or 3) metabolic requirements for protein are substantially increased, as extensive burns.

ישראל - עברית - Ministry of Health

teva medical ltd - glucose monohydrate - תמיסה לאינפוזיה - glucose monohydrate 50 % - glucose - glucose - dextrose 50 % injection is indicated as a caloric component in a parenteral nutrition regimen. it is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) the alimentary tract cannot/should not be used 2) gastrointestinal absorption of protein is impaired or 3) metabolic requirements for protein are substantially increased , as with extensive burns.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - glucose monohydrate - תמיסה לאינפוזיה - glucose monohydrate 5.5 %w/v - glucose - glucose - for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

ישראל - עברית - Ministry of Health

sanofi israel ltd - imiglucerase - אבקה להכנת תמיסה מרוכזת לעירוי - imiglucerase 400 u/vial - imiglucerase - imiglucerase - for the long term enzyme replacement therapy for patients with a confirmed diagnosis of type 1 gaucher disease that results in one or more of the following conditions: - anemia - thrombocytopenia - bone disease - hepatomegaly or splenomegaly.

ישראל - עברית - Ministry of Health

lapidot medical import and marketing ltd - glucose as monohydrate - תמיסה לאינפוזיה - glucose as monohydrate 5 g / 100 ml - glucose - glucose - vehicle solution for supplementary medication. energy supply, hypertonic dehydration.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - glucose as monohydrate - תמיסה לאינפוזיה - glucose as monohydrate 20 g / 100 ml - glucose - glucose - dextrose injection is indicated as a caloric compnent in parenteral nutrition regimen. it is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) the alimentary tract cannot/should not be used 2) gastrointestinal absorption of protein is impaired or 3) metabolic requirement sfor protein are substantially increases as extensive burns.